MD Anderson Research Highlights for November 21, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Modified drug reverses chronic pain with reduced side effects
Oxidative stress, which can cause...
MD Anderson and Jazz Pharmaceuticals announce five-year collaboration to evaluate zanidatamab in HER2-expressing cancers
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration...
MD Anderson Research Highlights: ESMO 2023 Special Edition
ABSTRACTS: LBA71, 1088MO, 95MO, LBA48, 1082O, 1085O, LBA34, 243MO
The University of Texas MD Anderson Cancer Center’s Research Highlights...
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
ABSTRACT: 4008
HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer (BTC), researchers from The University of Texas MD Anderson Cancer Center reported at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The study results also were published today in The Lancet Oncology.
In the first cohort of the global Phase...
MD Anderson Research Highlights: ASCO 2023 Special Edition
ABSTRACTS: 398868, 425082, 6546, 3501, 6008, 9502, 9011, 9008
CHICAGO ― The University of Texas MD Anderson Cancer Center’s Research...
MD Anderson Research Highlights for April 19, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for November 30, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor...
Study links BAP1 protein to tumor suppression in kidney, eye, bile duct and mesothelioma cancers
Researchers at The University of Texas MD Anderson Cancer Center have shown how BRCA-associated protein 1 (BAP1) serves as a tumor suppressor...
First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple cancers
A phase I, first-in-human study led by The University of Texas MD Anderson Cancer Center reveals for the first time, an investigational drug...